The pitfalls of pharmaceutical marketing
以2007年Adcock Ingram公司直接向消费者宣传其处方药Myprodol而遭监管机构处罚为例，揭示了药品营销中违反法规的风险。
During 2007, Adcock Ingram incurred the wrath of the Medicines Control Council when it advertised its flagship product, Myprodol, directly to consumers. According to the Medicines Act, pharmaceutical products classified as schedule two or higher may not be advertised directly to the public, but only to medical practitioners, pharmacists and individuals authorized to prescribe prescription drugs. Classified as a schedule three drug, Myprodol falls into this restricted category.